2024-02-02 00:32:22
Hanmi Pharmaceutical’s ‘Raspirin’, Korea’s first aspirin + PPI combination drug [사진=한미약품 제공]
[헬스코리아뉴스 / 이순호] A combination drug that can alleviate concerns regarding gastrointestinal disorders and bleeding side effects that may occur when taking aspirin for a long period of time, which is used as a primary recommended medication for high-risk cardiovascular disease prevention and for patients who have undergone stent insertion procedures, has been developed for the first time in Korea and is listed on the prescription list.
Hanmi Pharmaceutical is the first in Korea to develop and exclusively launch ‘Raspirin Capsule (hereinfollowing referred to as Raspirin)’ 100/5mg, a combination drug containing 100mg of aspirin and 5mg of rabeprazole, one of the ingredients of a proton pump inhibitor (PPI), in one capsule. It was announced on the 2nd.
According to Hanmi Pharmaceutical, ‘Raspirin Capsule’ uses polycap technology to reduce interactions between ingredients, while allowing drug absorption through independent dissolution of each ingredient. PolyCap is Hanmi Pharmaceutical’s proprietary formulation technology that minimizes drug-drug interactions while maintaining the release patterns of each of the two components. In addition, to complement the properties of the rabeprazole ingredient, moisture-proof coating was applied to increase stability.
An official from Hanmi Pharmaceutical said, “It is more economical than taking aspirin and PPI separately, so it will also contribute to reducing insurance finances.”
© Health Korea News Unauthorized reproduction and redistribution prohibited
1706845087
#Hanmi #Pharmaceutical #exclusively #launches #Koreas #aspirin #PPI #combination #drug #Raspirin
